Literature DB >> 1385335

Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues.

L Borsi1, B Carnemolla, G Nicolò, B Spina, G Tanara, L Zardi.   

Abstract

Functionally different tenascin (TN) isoforms, containing varying numbers of a 91 amino-acid motif resembling the fibronectin type-III homology repeat, may be generated by alternative splicing of the TN primary transcript. In fact, only the TN isoform containing the alternatively spliced region can induce loss of focal adhesion in cultured cells and seems to be able to facilitate cell migration. We examined the patterns of alternative splicing of the TN primary transcript in normal, hyperplastic and neoplastic breast tissues, and found that, in all the invasive breast carcinomas analyzed, the relative amount of TN mRNA in which the alternatively spliced region was included was about 10 times higher than in RNA from normal breast tissues. A similar result was observed in phyllodes tumors and in those fibroadenomas which showed very high stromal cellularity. Western-blot analysis using different monoclonal antibodies showed the same pattern as that seen in Northern blotting. The data reported here suggest that, in the breast, expression of the high-molecular-mass TN isoform is a marker of stromal element proliferation and that, in invasive breast carcinomas, this TN isoform could play a role in generating a permissive environment for proliferation, invasion and metastasis of neoplastic epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385335     DOI: 10.1002/ijc.2910520504

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.

Authors:  Kerstin Galler; Kerstin Junker; Marcus Franz; Julia Hentschel; Petra Richter; Mieczyslaw Gajda; Angela Göhlert; Ferdinand von Eggeling; Regine Heller; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2011-11-11       Impact factor: 4.304

Review 2.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

3.  High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies.

Authors:  O Driemel; R Dahse; A Berndt; H Pistner; S G Hakim; L Zardi; T E Reichert; H Kosmehl
Journal:  Clin Oral Investig       Date:  2006-11-17       Impact factor: 3.573

4.  Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front.

Authors:  Marcus Franz; Torsten Hansen; Petra Richter; Laura Borsi; Frank-D Böhmer; Peter Hyckel; Peter Schleier; Detlef Katenkamp; Luciano Zardi; Hartwig Kosmehl; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2005-12-13       Impact factor: 4.304

5.  Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II.

Authors:  C Y Chung; J E Murphy-Ullrich; H P Erickson
Journal:  Mol Biol Cell       Date:  1996-06       Impact factor: 4.138

6.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

7.  Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.

Authors:  Luigi Aloj; Laura D'Ambrosio; Michela Aurilio; Anna Morisco; Ferdinando Frigeri; Corradina Caraco'; Francesca Di Gennaro; Gaetana Capobianco; Leonardo Giovannoni; Hans D Menssen; Dario Neri; Antonio Pinto; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

8.  Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development.

Authors:  N Thomasset; A Lochter; C J Sympson; L R Lund; D R Williams; O Behrendtsen; Z Werb; M J Bissell
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

9.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.